<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069312</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00179281</org_study_id>
    <nct_id>NCT04069312</nct_id>
  </id_info>
  <brief_title>Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)</brief_title>
  <acronym>RELIANCE</acronym>
  <official_title>Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to
      compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate
      regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate
      regimen) to prevent hospitalization or death in a patients at high risk for COPD
      exacerbations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RELIANCE is a U.S.-based pragmatic clinical trial funded by the Patient-Centered Outcomes
      Research Institute (PCORI) to compare long-term use of roflumilast vs. azithromycin in up to
      3,200 patients. It is intended to support hospital efforts to reduce the risk of all-cause
      hospitalization and reduce pre-mature deaths in individuals with chronic obstructive
      pulmonary disease (COPD) who have been hospitalized in the prior year for a COPD
      exacerbation. The COPD Patient Powered Research Network (PPRN) and affiliated investigators
      will conduct the trial in sites in the U.S.

      Both roflumilast and azithromycin have been shown to reduce the risk of COPD exacerbations
      compared to placebo. However, there has not been a head-to-head comparison of the two
      medications. So, the relative harms and benefits of the two medications are unknown. Eligible
      patients will be randomized (1:1) to receive either a prescription for roflumilast or a
      prescription for azithromycin, and will be followed for at least 6 and up to 36 months. The
      primary endpoint is the combined outcome of all-cause hospitalization or death; the secondary
      endpoints include premature treatment discontinuation, patient-reported adverse effects, and
      physical, social, and emotional health. Patients will be enrolled at participating clinical
      sites and follow up data will be collected via an online patient portal or via a call center.
      Baseline and outcome data will also be collected from site medical records and
      administrative/claims databases.

      Pragmatic, non-inferiority trial using an intention-to-treat analysis to evaluate whether
      daily azithromycin is non-inferior to daily roflumilast in patients at high risk of COPD
      exacerbations. The investigators will randomize individual patients to receive prescriptions
      for roflumilast or azithromycin (1:1 ratio), stratified by site and current smoking status
      (yes/no).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2020</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial is a parallel, pragmatic non-inferiority trial with two treatment groups, roflumilast and azithromycin. Up to 3,200 participants will be randomized (1:1) to receive a prescription for one of the two treatments. Treatment assignments will be stratified by site and smoking status (former versus current) using a permuted block design with multiple block sizes.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Treatment assignments will be concealed prior to randomization. Once a patient is assigned to receive a treatment, the clinician, Site Coordinator and patient will not be masked. i.e., they will know the treatment assignment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of All-cause hospitalizations</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All-cause hospitalizations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of All-cause deaths</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All-cause deaths</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of All-cause individual events</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>All-cause individual events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical function as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>Based on the scoring scale; a score of 5 is the most favorable and a score of 1 is least favorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in problems with sleep as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>1 is least favorable and 5 is most favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fatigue as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>0 is most favorable and 4 and least favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>Score of 1 is most favorable and 5 is least favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression as assessed by the PROMIS scale</measure>
    <time_frame>Baseline, 3 months, 6 months and every 6 months up to 36 months</time_frame>
    <description>1 is most favorable and 5 is least favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence as assessed by patient self-report</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Medication Adherence will be assessed by self-report via Call Center or Patient Portal; Medicare claims data in a subset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that switch to alternate study medication</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Patient will be assigned either azithromycin or roflumilast at randomization. We will assess any switch to either roflumilast from azithromycin or azithromycin from roflumilast by self-report via Call Center or Patient Portal, query of clinic staff; Medicare claims data in a subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Out of pocket cost for study medication</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Out of pocket costs for roflumilast of azithromycin by self-report via Call Center or Patient Portal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Weight in lbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that discontinued medication</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>This will be collected by self-report via Call Center or Patient Portal; query of clinic staff; Medicare claims data in a subset</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease Severe</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Roflumilast arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months</description>
    <arm_group_label>Roflumilast arm</arm_group_label>
    <other_name>Daliresp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months</description>
    <arm_group_label>Azithromycin arm</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient and treating clinician considering treatment intensification with roflumilast
             or azithromycin to reduce the risk of COPD exacerbations

          -  Age â‰¥ 40 years

          -  Current or past smoker of at least 10 pack-years

          -  Diagnosis of severe COPD and associated chronic bronchitis

          -  Hospitalized with a diagnosis of COPD exacerbation in the past 12 months

          -  Current medications include inhaled Long Acting Muscarinic Antagonist (LAMA), Long
             Acting Beta Agonist (LABA) /LAMA, or Inhaled Corticosteroids (ICS) /LABA

          -  English or Spanish speaking

        Exclusion Criteria:

          -  Unable or declines to provide informed consent;

          -  Declines to provide social security number or health insurance claims number (as
             applicable)

          -  History of intolerance to azithromycin or roflumilast that the patient or patient's
             treating clinician considers sufficiently serious to avoid either treatment option;

          -  Current treatment with long-term (more than 30 days) roflumilast or azithromycin
             (previous treatment with 1 or more doses of azithromycin or roflumilast is not an
             exclusion criterion, as long as the patient and clinician are seeking treatment
             intensification options and would be willing to use azithromycin or roflumilast, as
             per randomized treatment assignment.)

          -  Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide
             antibiotic;

          -  History of cholestatic jaundice/hepatic dysfunction associated with prior use of
             azithromycin

          -  Moderate to severe liver impairment (Child-Pugh B or C)

          -  Current pregnancy

          -  Any other clinician-determined exclusion as per the clinician's clinical practice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Krishnan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois, Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Wise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gem Roy, MD</last_name>
    <phone>4432875796</phone>
    <email>groy2@jhu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Surya Bhatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lynn Gerald, PhD, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark Avdalovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Hanley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ravi Kalhan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Valentin Centurion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valentin Centurion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore Hospital</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shashi Bellam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward Hines, Jr.VA Hospital</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Majid Afshar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Majid Afshar, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alejandro Comellas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Leonardo Seoane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nirupama Putcha, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Health</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Victor Pinto-Plata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Meilan Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Ouellette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri, Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gary Salzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mario Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sidney Braman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bradley Drummond, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Timothy Scialla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rodney Folz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Umur Hatipoglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philip Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Mularski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gerard Criner, MD, FACP, FACCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frank Sciurba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Charlie Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White (BSW) Health-North</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mark Millard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health and Services</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Allison Lambert, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valeriie Bonne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>COPD</keyword>
  <keyword>Roflumilast</keyword>
  <keyword>Daliresp</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

